NAD+ and glutathione injections: evidence, risks, and expectations

NAD+ injections: what does human research tell us?

A 2026 retrospective pilot compared commercially administered intravenous NAD+ and nicotinamide riboside infusions. It examined tolerability and other measures using existing records, and reported infusion-related symptoms among NAD+ recipients. A small observational pilot is not proof that a program extends life or delivers broad wellness benefits.

Read the method before the marketing summary. Research on a precursor, an oral supplement, or an intravenous infusion does not automatically describe a different ingredient or an under-the-skin injection. Ask which study matches the product, route, population, and outcome being offered.

Sources: Frontiers in Aging: NAD+ versus NR retrospective IV tolerability pilot (2026)

NAD+ ingredient quality is a separate concern

FDA has warned about using food-grade ingredients to compound sterile NAD+ injections. Its communication describes adverse-event reports including severe chills, shaking, vomiting, and fatigue. Such reports flag concerns but do not, by themselves, establish how often an event occurs across all products.

When considering an injection, ask the clinician and pharmacy to explain the source of the finished product and how questions about quality or a reaction are handled. A discussion focused only on the ingredient’s biological role leaves out the preparation being administered.

Sources: FDA: Ingredients suitable for sterile compounding, including NAD+

Glutathione injections: distinguish claims from preparation risks

In an August 27, 2026 communication, FDA described reports involving at least 30 patients with adverse events after IV glutathione alone or with other ingredients. FDA reiterated that dietary-supplement-grade glutathione should not be used in injectable preparations. This is a current ingredient-quality concern, not a clinical demonstration of a wellness benefit.

If a program promises “detox,” ask what that means in measurable terms. Which condition, symptom, or clinical outcome is being addressed? What study supports that outcome for the actual injectable formulation? A broad label can hide the absence of a clearly defined claim.

Sources: FDA: Dietary-supplement-grade glutathione and injectables, August 27, 2026

Where Lipo-B with B12 fits

Treat “Lipo-B with B12” as a catalog name that requires clarification. Ask for the full ingredient list, concentrations, and reason for each ingredient. Do not infer a standard formulation from the name.

NIH states that B12 supplements do not improve energy or endurance in people who already have adequate intake. Evaluating a possible deficiency is different from promising extra energy or weight loss to someone without one. Ask whether a specific medical finding, rather than a general wellness goal, is driving the recommendation.

Sources: NIH Office of Dietary Supplements: Vitamin B12

A practical checklist for wellness-injection claims

Before making a decision, ask for a written description of the proposal that you can review outside the sales conversation. The following questions help separate an appealing promise from an assessable plan.

• What exact improvement is expected, and how would it be measured?
• Was that outcome demonstrated in humans receiving this same formulation and route?
• What are the main uncertainties and the known risks?
• Who prepares the product, who administers it, and who provides follow-up?
• What should happen if there is no meaningful improvement?
• What is the full cost of the proposed course, including appointments or monitoring?

Keep expectations connected to the evidence

A persuasive explanation should leave room for uncertainty. If a study only measured short-term tolerability, it cannot answer a question about long-term longevity. If a program changes several things at once, a personal improvement does not identify which change caused it. Those distinctions are useful even when a treatment is presented by a professional.

Toven lists NAD+, glutathione, and Lipo-B with B12 with product information and purchase options. A paid order remains subject to clinical review and pharmacy fulfillment requirements. This guide does not recommend an injection. Our GLP-1 formulation guide covers B12 in a different context, and our peptide-safety guide explains how to evaluate claims about other catalog ingredients.